DexCom Inc.
Dexcom, Inc. (DXCM)
Overview
Dexcom is a medical device company that designs, manufactures, and markets continuous glucose monitoring (CGM) systems for people with diabetes and, more recently, for broader metabolic health monitoring. Headquartered in San Diego, California, and founded in 1999, Dexcom operates in the Medical Devices industry within the Healthcare sector, went public in 2005, and is a component of both the Nasdaq-100 and S&P 500. The company employs approximately 11,100 people, manufactures its sensors at facilities in Mesa, Arizona; Batu Kawan, Malaysia; and Athenry, Ireland, and generated about $4.66 billion in fiscal 2025 revenue (up nearly 16% from 2024's $4.03 billion), with a market capitalization of roughly $34 billion.
What They Do & How They Make Money
Dexcom makes wearable sensor-based devices that continuously measure a user's glucose (blood sugar) level in real time and transmit that data via Bluetooth to a smartphone app, smartwatch, or dedicated receiver — eliminating or greatly reducing the need for the traditional fingerstick blood test that diabetics have relied on for decades. The business model is a classic "razor-and-blade" recurring-revenue setup: Dexcom sells a small transmitter/reader component once (or infrequently), but the real revenue engine is the disposable sensor, which patients must replace roughly every 10–15 days, generating predictable, recurring purchases for as long as a patient remains on therapy. This creates a subscription-like revenue stream even though Dexcom is a hardware company, and it means growth is driven by expanding the number of active users (new patients starting CGM therapy, and existing fingerstick users switching to CGM) as much as by pricing. Dexcom sells both through durable-medical-equipment/pharmacy channels reimbursed by insurance (Medicare, Medicaid, and private payers covering its prescription G6 and G7 systems for people with diabetes) and, since 2024, directly to consumers over the counter through Stelo, a lower-cost glucose biosensor aimed at the much larger population of people with prediabetes or general metabolic-health interest who don't have a diabetes diagnosis — opening a significant new addressable market beyond its traditional insulin-using patient base. The company also earns revenue through strategic partnerships that integrate its glucose data into other companies' devices and apps, including insulin pump makers (Tandem Diabetes Care, Insulet's Omnipod) that build "automated insulin delivery" systems using Dexcom's real-time glucose readings to adjust insulin dosing automatically.
Business Segments
Dexcom does not organize its financial reporting into multiple distinct operating segments in the way a diversified conglomerate would; it operates and reports substantially as a single business — continuous glucose monitoring systems and related technology — with its growth increasingly described internally along product and channel lines rather than formal reportable segments:
- Core CGM systems (G6/G7) — prescription, insurance-reimbursed sensors and transmitters for people with Type 1 or Type 2 diabetes, sold globally through pharmacy and durable-medical-equipment channels; this remains the large majority of revenue. The G7, launched in December 2022, is a smaller, more accurate, and more affordable next-generation sensor that has driven both new-patient adoption and existing-user upgrades.
- Stelo and consumer/OTC metabolic health — an over-the-counter biosensor (not requiring a prescription) launched in 2024 for adults with prediabetes or Type 2 diabetes not on insulin, and more broadly for general glucose/metabolic awareness; recognized among Time Magazine's Best Inventions of 2024 and representing Dexcom's push to expand beyond its traditional insulin-using base into a much larger wellness-oriented market.
- Partner/data-integration revenue — technology licensing and integration fees from partnerships with insulin pump and digital-health companies (Tandem, Insulet, and data platforms), embedding Dexcom's sensor data into third-party automated insulin delivery systems and health apps.
Geographically, Dexcom generates the majority of its revenue in the United States, with an internationally expanding base in Europe and other markets.
Competitors
- Direct CGM competitors: Abbott Laboratories (FreeStyle Libre, the largest CGM competitor globally by user count) and Medtronic (Guardian CGM systems, often bundled with its own insulin pumps).
- Adjacent diabetes-device makers: Insulet (Omnipod insulin pumps) and Tandem Diabetes Care (t:slim insulin pumps) are technology partners for automated insulin delivery but also compete for the broader diabetes-technology wallet.
- Broader medical-device/healthcare peers commonly tracked alongside Dexcom for market comparison include Boston Scientific, Stryker, Intuitive Surgical, Edwards Lifesciences, and HealthEquity.
Competitive Position
Dexcom has built its position as a technology leader in CGM accuracy, form factor, and app/software integration, and its G7 platform is marketed as one of the most accurate CGM systems available. Its deep, multi-year integration partnerships with the two leading independent insulin pump makers (Tandem and Insulet) give it a strong foothold in the fast-growing automated insulin delivery ("artificial pancreas") category, where CGM accuracy is safety-critical, creating switching costs and technical lock-in that are hard for a new entrant to replicate quickly. The 2024 launch of Stelo, aimed at the far larger prediabetes and general-wellness population rather than just diagnosed diabetics, represents a significant expansion of Dexcom's addressable market beyond the roughly 8 million U.S. insulin users who have been the industry's traditional core CGM customer base, tapping into broader consumer interest in metabolic health and glucose tracking (a trend amplified by wellness and fitness culture).
The primary competitive risk is Abbott's FreeStyle Libre franchise, which has a larger global user base, a lower price point in many markets, and has moved aggressively into the same over-the-counter/consumer space that Stelo targets, intensifying head-to-head competition for both prescription and OTC glucose-monitoring customers. Reimbursement and pricing pressure from insurers and government payers (Medicare, Medicaid, and international health systems) is a persistent risk, as is potential pricing compression as CGM adoption matures and competition increases. Dexcom is also exposed to manufacturing and supply-chain concentration risk given its reliance on a limited number of production facilities, regulatory risk tied to FDA approval processes for new sensor generations, and the broader risk that continuous glucose monitoring could eventually be commoditized as more entrants (including large diversified medtech firms) invest in the category. Longer term, GLP-1 weight-loss and diabetes drugs (such as Ozempic and Mounjaro) present a nuanced risk/opportunity: they could reduce disease progression and insulin dependence for some patients even as they expand the overall population engaged in metabolic health monitoring that Stelo is designed to capture.